Keros Therapeutics, Inc.
KROS
$14.91
$0.151.02%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -91.40% | 6,844.31% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -91.40% | 6,844.31% | |||
| Cost of Revenue | -10.69% | 138.05% | |||
| Gross Profit | -115.59% | 24.04% | |||
| SG&A Expenses | 37.96% | -1.58% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.06% | 5.17% | |||
| Operating Income | -126.19% | 385.50% | |||
| Income Before Tax | -120.77% | 446.62% | |||
| Income Tax Expenses | -122.12% | 3,247.67% | |||
| Earnings from Continuing Operations | -120.68% | 422.54% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -120.68% | 422.54% | |||
| EBIT | -126.19% | 385.50% | |||
| EBITDA | -125.89% | 387.94% | |||
| EPS Basic | -120.65% | 420.78% | |||
| Normalized Basic EPS | -120.74% | 444.71% | |||
| EPS Diluted | -120.99% | 417.27% | |||
| Normalized Diluted EPS | -120.98% | 440.83% | |||
| Average Basic Shares Outstanding | 0.13% | 0.55% | |||
| Average Diluted Shares Outstanding | -1.00% | 1.69% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||